Azitra, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company’s platform leverages proprietary bacterial strains to modulate the skin microbiome, with the goal of restoring healthy skin function and alleviating symptoms of inflammatory and infectious skin disorders.
Azitra’s lead product candidates include AZT-02, a topical formulation designed to treat atopic dermatitis by delivering beneficial commensal bacteria directly to affected skin. Additional programs in the pipeline are targeting acne, seborrheic dermatitis, and other skin ailments where dysbiosis of the microbiome plays a key role. These candidates are being evaluated in preclinical studies and early-stage clinical trials.
Founded in 2017 through a spin-out of microbiome research from Harvard University, Azitra is headquartered in Cambridge, Massachusetts. The company also maintains research collaborations across Europe and North America, positioning itself to conduct multi-site clinical development and ultimately support regulatory filings in both the United States and the European Union.
Azitra’s leadership team is led by President and CEO David Whitehouse, who brings extensive experience in biotech operations and clinical development. The scientific advisory board comprises experts in dermatology, microbiology, and translational medicine, guiding the company’s R&D strategy and ensuring rigorous development of its microbiome therapeutics.
AI Generated. May Contain Errors.
